Please do not leave this page until complete. This can take a few moments.
After being delisted on NASDAQ last week, Holliston biotech Biostage has laid off 17 of its 24 employees, a 71-percent reduction, the company announced Thursday.
The company attributed its financial situation to what it called a breach and failure to fund by Dallas investment firm First Pecos, which had agreed to a $3 million investment with Biostage, but the agreement feel through.
According to Biostage, First Pecos claims Biostage is in breach of its obligations pursuant to the investment agreement. Biostage claims it met new demands of First Pecos, but the company still did not deliver the funding.
As a result, Biostage's current financial obligations exceed its cash on hand.
The layoffs will cost the company $153,000 in one-time termination benefits in the fourth quarter. The company will move forward with a core group of scientists and engineers who have been with the company and helped develop its organ transplant technology.
The company finds itself in a weakened financial position, said Jim McGorry, Biostage’s CEO, in a press release.
“After months of good faith negotiations by Biostage, we sincerely believed we had a solid path forward for our technology and shareholders,” he said. “We believe the fact pattern of constant funding delays and increasing demands demonstrates First Pecos had a different agenda.”
According to Biostage, First Pecos delivered a notice on Tuesday indicating the agreement has been terminated due to alleged breaches by Biostage. In addition, First Pecos is demanding a $500,000 termination fee, Biostage said.
Biostage refutes it was in breach of the agreement and does not believe First Pecos is entitled to termination fees.
“The company is reviewing all of its rights and remedies against First Pecos,” Biostage said.
Biostage was delisted from NASDAQ as of last Friday after a yearlong process because its stock price fell below the minimum required. The company’s stock is now listed on the OTCQB marketplace.
Biostage claimed the delisting was due, in part, to the break down in agreement with First Pecos.
Read more
Biostage names regenerative medicine expert to board
Stay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Sign upWorcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
SubscribeWorcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
See Digital EditionStay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Worcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
Worcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments